NEULANDLAB

Neuland Laboratories Limited

What the six lenses say about NEULANDLAB — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹19542.0
2026-07-10
VWAP · 1Y anchor
₹15254
+28.1% from VWAP
P/E · TTM
68.9×
TTM EPS ₹283.7
52-week range
100%
position low→high
RSI(14)
78
momentum

Own sector index

Healthcare
Overweight

1M

+5.5%

3M

+14.9%

1Y

+12.8%

Breadth >EMA21

68%

How NEULANDLAB’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
10.0
avg conviction decile
Leadership
1/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD10100

The actual numbers

Price vs VWAP (1y)+28.1%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+27.6%
Price vs 50-EMA+13.5%
RSI(14)78
RS vs Nifty 500 · 3M+27.4%
RS vs sector · 3M+15.8%
52-week range100%
Volume vs 30d avg0.50×
Volume vs 60d avg0.42×
ATR(14) · volatility639.5
Bollinger width · vol contraction0.184
FundamentalD1090

The actual numbers

Return on equity (ROE)21.4%
Return on capital (ROCE)26.6%
Operating margin25.3%
Net margin18.0%
Revenue growth · YoY+37.0%
EPS growth · YoY+39.9%
Debt / equity0.16×

Full 8-quarter history in the financials table below.

ValuationD28

The actual numbers

P/E (TTM)68.9×
TTM EPS₹283.7
52-week range100%
CatalystD540

The actual numbers

Earnings & momentum42
Capital actions11
Governance89

Every filing in the corporate-announcements panel below.

FlowD1068

The actual numbers

Promoter holding32.6%
Delivery · 30d avg43.9%
Up/down-day asymmetry5.4pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D10 ) ÷ 2 = 10.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
97
Conviction score 97/100 · avg-decile strength 10.0/10

Policy

Government policy · Healthcare

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+3.1pp
+3.8pp
+12.1pp
+31.1pp
+39.0pp
+70.0pp
Nifty 500
Broad-market baseline
+2.7pp
+3.7pp
+11.5pp
+27.4pp
+33.9pp
+66.2pp
Sector
Own-sector index
+9.8pp
+15.8pp
+21.1pp
+51.7pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

NEULANDLAB daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
19542.00+653.00

Relative strength

RS vs baseline · rebased to 100

NEULANDLAB ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
245.62+6.41

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)440311398328293514440776
↳ change QoQ-29.3%+28.0%-17.6%-10.7%+75.4%-14.4%+76.4%
EBITDA (₹cr)14967146513415677307
EBITDA margin33.9%21.4%36.8%15.6%11.6%30.3%17.5%39.6%
PAT (₹cr)983310228149741213
↳ change QoQ-66.4%+209.3%-72.4%-50.0%+592.9%-57.7%+419.5%
Net margin22.3%10.6%25.5%8.5%4.8%18.9%9.3%27.5%
EPS (₹)76.2825.6079.1821.6810.8375.4931.62165.76
D/E
YoY growth · Mar '26Revenue +136.6% YoYPAT +660.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 5 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 16 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 May '26
    HIGHearnings
    Outcome of Board Meeting

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 12 May '26
    MEDIUMcapital
    Press Release (Revised)

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 12 May '26
    LOWgovernance
    Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 May '26
    LOWgovernance
    General Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 May '26
    HIGHearnings
    Outcome of Board Meeting

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 12 May '26
    MEDIUMcapital
    Press Release (Revised)

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 12 May '26
    MEDIUMearnings
    Investor Presentation

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 12 May '26
    MEDIUMcapital
    Press Release

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 12 May '26
    MEDIUMcapital
    Dividend

    A dividend declaration — a cash return to shareholders.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds NEULANDLAB

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Healthcare